Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated (VRTX)
Compare

Vertex Pharmaceuticals Incorporated (VRTX) Price/FCF Ratio: 30.18

popular:market cap|pe ratio|revenue|price history|total return

Is Vertex Pharmaceuticals Incorporated’s Price/FCF ratio high or low?

Vertex Pharmaceuticals Incorporated's Price/FCF ratio of 30.18 is 11% above its 5-year average of 27.14, around the middle of its 5-year range (16.11–40.03).

The Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX) is 30.18. It is below its 12-month average by 8.75% (33.08).

P/E Ratio|FCF Growth|Operating Margin|All Metrics

VRTX Price/FCF Ratio Chart

VRTX Price/FCF Ratio
30.18+8.80% 1Y
Zoom

VRTX Average Price/FCF Ratio Chart

VRTX Current vs Average Price/FCF Ratio Chart

VRTX Price/FCF Ratio Metrics

PRICE/FCF RATIO

30.18

PRICE/FCF RATIO AVG TTM

33.08

PRICE/FCF RATIO AVG 3Y

30.07

PRICE/FCF RATIO AVG 5Y

27.14

PRICE/FCF RATIO AVG 10Y

47.08

PRICE/FCF RATIO AVG 15Y

86.66

PRICE/FCF RATIO AVG 20Y

86.66

CURRENT VS TTM AVG

-8.75%

CURRENT VS 3Y AVG

+0.35%

CURRENT VS 5Y AVG

+11.20%

CURRENT VS 10Y AVG

-35.89%

CURRENT VS 15Y AVG

-65.17%

CURRENT VS 20Y AVG

-65.17%

VRTX Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B30.1833.0830.0727.14
Bristol-Myers Squibb Company (BMY)$114.14B9.597.748.439.56
Medtronic plc (MDT)$103.04B19.0522.3422.5623.73
CVS Health Corporation (CVS)$125.16B16.9715.7614.2611.77
Danaher Corporation (DHR)$130.25B24.7929.0229.6928.00
Elevance Health Inc. (ELV)$87.43B13.7618.0141.2730.19
Cigna Corporation (CI)$78.25B10.2012.9211.5011.57
Pfizer Inc. (PFE)$146.36B15.5013.8919.4416.06
Intuitive Surgical, Inc. (ISRG)$146.44B52.5281.09163.31127.32
Gilead Sciences, Inc. (GILD)$151.21B14.9216.6513.8612.23

Free Cash Flow Valuation

P/FCF Ratio

30.2

FCF Yield

3.31%

Vertex Pharmaceuticals Incorporated Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Vertex Pharmaceuticals Incorporated Price/FCF Ratio FAQ

What is the Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The Price/FCF ratio for VRTX stock is 30.18.
Is Vertex Pharmaceuticals Incorporated's Price/FCF ratio high or low?
Vertex Pharmaceuticals Incorporated's Price/FCF ratio of 30.18 is 11% above its 5-year average of 27.14, around the middle of its 5-year range (16.11–40.03).
What is the TTM average Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The TTM average Price/FCF ratio for VRTX stock is 33.08.
What is the 3Y average Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 3Y average Price/FCF ratio for VRTX stock is 30.07.
What is the 5Y average Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 5Y average Price/FCF ratio for VRTX stock is 27.14.
What is the 10Y average Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 10Y average Price/FCF ratio for VRTX stock is 47.08.
What is the 15Y average Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 15Y average Price/FCF ratio for VRTX stock is 86.66.
What is the 20Y average Price/FCF ratio for Vertex Pharmaceuticals Incorporated (VRTX)?
The 20Y average Price/FCF ratio for VRTX stock is 86.66.

Vertex Pharmaceuticals Incorporated Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-1030.18
2026-06-0930.79
2026-06-0830.60
2026-06-0530.87
2026-06-0430.51
2026-06-0329.59
2026-06-0229.36
2026-06-0130.28
2026-05-2930.92
2026-05-2830.94
2026-05-2730.20
2026-05-2630.11
2026-05-2230.02
2026-05-2129.95
2026-05-2029.73
2026-05-1930.00
2026-05-1830.16
2026-05-1530.18
2026-05-1431.11
2026-05-1331.30
2026-05-1230.97
2026-05-1130.06
2026-05-0829.69
2026-05-0729.36
2026-05-0629.54
2026-05-0529.31
2026-05-0434.47
2026-05-0133.99
2026-04-3034.27
2026-04-2933.94
2026-04-2834.49
2026-04-2734.16
2026-04-2434.50
2026-04-2334.89
2026-04-2235.10
2026-04-2135.01
2026-04-2035.22
2026-04-1735.38
2026-04-1634.93
2026-04-1535.42
2026-04-1435.63
2026-04-1335.29
2026-04-1034.98
2026-04-0935.83
2026-04-0835.60
2026-04-0734.63
2026-04-0634.83
2026-04-0235.18
2026-04-0135.86
2026-03-3135.81
2026-03-3035.54
2026-03-2734.73
2026-03-2636.38
2026-03-2536.48
2026-03-2435.97
2026-03-2336.18
2026-03-2036.40
2026-03-1936.73
2026-03-1836.21
2026-03-1737.09
2026-03-1637.37
2026-03-1337.63
2026-03-1238.34
2026-03-1139.48
2026-03-1040.03
2026-03-0936.96
2026-03-0636.62
2026-03-0536.95
2026-03-0438.32
2026-03-0338.03
2026-03-0238.97
2026-02-2739.84
2026-02-2638.50
2026-02-2538.73
2026-02-2439.09
2026-02-2338.57
2026-02-2038.24
2026-02-1937.63
2026-02-1837.71
2026-02-1738.27
2026-02-1339.41
2026-02-1235.90
2026-02-1135.60
2026-02-1035.78
2026-02-0936.35
2026-02-0636.89
2026-02-0535.42
2026-02-0436.32
2026-02-0335.94
2026-02-0236.43
2026-01-3036.27
2026-01-2936.72
2026-01-2836.89
2026-01-2736.60
2026-01-2636.81
2026-01-2336.16
2026-01-2236.07
2026-01-2135.60
2026-01-2034.12
2026-01-1634.07
2026-01-1533.88
2026-01-1434.70
2026-01-1335.10
2026-01-1235.55
2026-01-0935.81
2026-01-0836.25
2026-01-0737.37
2026-01-0636.15
2026-01-0534.64
2026-01-0234.90
2025-12-3135.00
2025-12-3035.02
2025-12-2935.49
2025-12-2635.73
2025-12-2435.74
2025-12-2335.45
2025-12-2235.53
2025-12-1935.21
2025-12-1834.53
2025-12-1734.70
2025-12-1635.12
2025-12-1535.18
2025-12-1234.89
2025-12-1134.42
2025-12-1034.32
2025-12-0933.73
2025-12-0834.12
2025-12-0535.16
2025-12-0435.30
2025-12-0335.75
2025-12-0233.44
2025-12-0132.85
2025-11-2833.47
2025-11-2633.36
2025-11-2533.18
2025-11-2432.73
2025-11-2132.94
2025-11-2032.60
2025-11-1932.50
2025-11-1833.62
2025-11-1733.50
2025-11-1433.74
2025-11-1333.54
2025-11-1233.52
2025-11-1133.13
2025-11-1032.51
2025-11-0731.61
2025-11-0632.13
2025-11-0532.19
2025-11-0432.55
2025-11-0331.51
2025-10-3131.48
2025-10-3031.06
2025-10-2930.86
2025-10-2831.25
2025-10-2731.08
2025-10-2431.17
2025-10-2331.27
2025-10-2231.55
2025-10-2131.53
2025-10-2031.00
2025-10-1730.83
2025-10-1630.23
2025-10-1530.18
2025-10-1430.50
2025-10-1330.14
2025-10-1030.17
2025-10-0930.69
2025-10-0831.16
2025-10-0730.35
2025-10-0629.81
2025-10-0329.84
2025-10-0230.25
2025-10-0129.90
2025-09-3028.97
2025-09-2929.24
2025-09-2628.54
2025-09-2528.25
2025-09-2427.86
2025-09-2328.09
2025-09-2228.34
2025-09-1928.34
2025-09-1828.64
2025-09-1728.64
2025-09-1628.95
2025-09-1529.09
2025-09-1229.19
2025-09-1129.40
2025-09-1028.74
2025-09-0929.33
2025-09-0829.24
2025-09-0529.30
2025-09-0429.36
2025-09-0329.34
2025-09-0229.67
2025-08-2928.93
2025-08-2829.00
2025-08-2728.78
2025-08-2628.64
2025-08-2528.77
2025-08-2229.23
2025-08-2129.40
2025-08-2029.17
2025-08-1928.91
2025-08-1828.84
2025-08-1529.06
2025-08-1428.87
2025-08-1329.29
2025-08-1228.69
2025-08-1127.70
2025-08-0827.12
2025-08-0727.79
2025-08-0628.53
2025-08-0527.74
2024-08-0137.33
2024-07-3136.59
2024-07-3037.10
2024-07-2936.77
2024-07-2636.56
2024-07-2536.34
2024-07-2436.23
2024-07-2336.19
2024-07-2236.60
2024-07-1936.28
2024-07-1836.03
2024-07-1736.05
2024-07-1636.09
2024-07-1536.23
2024-07-1236.08
2024-07-1136.33
2024-07-1036.29
2024-07-0935.87
2024-07-0835.57
2024-07-0535.03
2024-07-0334.71
2024-07-0234.97
2024-07-0134.78
2024-06-2834.60
2024-06-2734.88
2024-06-2634.99
2024-06-2534.97
2024-06-2435.06
2024-06-2134.60
2024-06-2034.79
2024-06-1834.49
2024-06-1734.96
2024-06-1435.48
2024-06-1335.36
2024-06-1235.12
2024-06-1135.54
2024-06-1035.67
2024-06-0735.65
2024-06-0635.84
2024-06-0535.65
2024-06-0435.06
2024-06-0334.71
2024-05-3133.61
2024-05-3032.70
2024-05-2932.56
2024-05-2832.99

Showing the most recent 260 of 2,595 data points. The chart above shows the full history.

Related Metrics

P/E RatioFCF GrowthOperating MarginAll Metrics

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

Boston, MA
6,100 employees
www.vrtx.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
View full financials